Summary
On November 1, 2012, DexCom, Inc. (DexCom) announced a significant financing event through a Form 8-K filing. The company entered into a new Loan Agreement with Silicon Valley Bank and Oxford Finance, LLC, securing up to $35 million in funding. This includes a $15 million revolving line of credit and up to $20 million in term loans. The proceeds are earmarked for general corporate purposes, providing DexCom with crucial capital for its operations and growth initiatives. The filing also details key terms of the debt, including interest rates, repayment schedules, and covenants. Notably, the loan is secured by substantially all of DexCom's assets, excluding intellectual property. The agreement imposes financial covenants, requiring DexCom to meet certain revenue targets, maintain an adequate liquidity ratio (Adjusted Quick Ratio), or achieve a satisfactory Fixed Charge Ratio to remain in compliance. This financing is a critical step for DexCom as it continues to develop and market its medical devices.
Key Highlights
- 1DexCom secured a new $35 million credit facility consisting of a $15 million revolving line of credit and up to $20 million in term loans.
- 2The financing was provided by Silicon Valley Bank and Oxford Finance, LLC.
- 3Proceeds from the loan agreement are intended for general corporate purposes.
- 4The revolving line of credit has a maturity date of November 1, 2015, and bears interest at prime rate plus 0.5%.
- 5The term loans have a maturity date of November 1, 2016, with initial advances in November 2012 and further availability through September 2013.
- 6The borrowings are secured by a first priority security interest in substantially all of DexCom's assets, excluding intellectual property.
- 7The loan agreement includes financial covenants related to revenue, liquidity (Adjusted Quick Ratio), or fixed charge coverage, offering DexCom flexibility in meeting compliance requirements.